• Got Questions? Call Us Today! Phone: 240-729-1432832-295-3065
  • You Can Email Us at: kingquean2@gmail.com

Infusion Therapy for COVID-19: How It Works


The FDA approved a monoclonal antibody IV treatment Emergency Use Authorization (EUA) in 2021. Medication is administered intravenously (IV) so it enters your bloodstream immediately. Monoclonal antibodies are made to prevent viral entry and attachment to human cells to neutralize the virus. In individuals who are at high risk for developing severe COVID-19, it is intended to reduce viral replication and may be beneficial in treating COVID-19.

Monoclonal antibodies are only prescribed by a healthcare professional. For those at high risk or already diagnosed with COVID-19, discuss treatment options with your doctor. This type of IV Covid-19 antibody infusion can be found only by qualified and certified providers, such as King & Quean’s Point Services LLC.

Aside from administering the Covid-19 vaccine in Texas, we also provide IV therapy to further prevent the virus from complicating your health.

For the monoclonal antibody treatment to work, it must be administered as early as possible, even if the symptoms of COVID-19 haven’t kicked into full gear. Therefore, even if you don’t yet feel that horrible, the sooner the administration, the better. Early intervention when symptoms are milder may help high-risk patients avoid illness progression that might otherwise necessitate hospitalization.

IV therapy for COVID-19 works just like IV vitamin infusion. It needs to be performed by a qualified nurse to guarantee the overall safety and success of the treatment.

Common side effects of this therapy are fever and/or chills, nausea, headache, low blood pressure, muscle aches, and more.

To learn more about IV for COVID-19, as well as other services, feel free to set an appointment with us. We also offer Covid-19 Testing in Houston, Texas.

This entry was posted in Infusion Therapy and tagged , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *